The Swiss biopharmaceutical company Light Chain Bioscience has developed a novel and unique class of human, bispecific antibodies dubbed κλ bodies, so-called because they combine a κ light ...

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions.

Sanyou Bio's Intelligent Super-trillion Molecule Discovery Platform consists of ten sub-platforms, encompassing a variety of molecular types. These i ...

Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...

These light chains are part of immunoglobulins, also called antibodies. But in this disease, light chains misfold and ...

Paradox is focused on the development of treatment for immunoglobulin light chain amyloidosis (AL amyloidosis ... platform and bringing much-needed antibody therapies to market.” ...

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...

Launched in 2023 and accessible through Alloy's Antibody Discovery Services unit, the ATX-CLC platform enables the expression of common light chain antibodies with full heavy chain diversity ...

Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, �lanc� aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle ...

Paradox Immunotherapeutics ("Paradox"), a pharmaceutical company focused on the development of innovative antibody therapies that treat protein misfolding diseases, today announced a $10 million ...